Research programme: PSMA ATAC therapeutics - Heidelberg Pharma Research

Drug Profile

Research programme: PSMA ATAC therapeutics - Heidelberg Pharma Research

Alternative Names: Anti-PSMA antibody-targeted amanitin conjugate - Heidelberg Pharma Research; Anti-PSMA ATAC; PSMA antibody drug conjugates - Heidelberg Pharma Research

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma Research
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 15 Apr 2018 Safety pharmacokinetics and pharmacodynamics data from a preclinical study in Prostate cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 18 Oct 2016 Research programme: PSMA ATAC therapeutics - Heidelberg Pharma is available for licensing as of 13 Oct 2016. http://www.heidelberg-pharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top